title: Severity of lipodystrophy is associated with decreased health-related quality of life.
abstract: The impact of lipodystrophy (LD) on quality of life is high, but it has not been demonstrated in literature. The objective of the study was to assess the impact of LD on the health-related quality of life (HRQOL) in HIV-infected people on highly active antiretroviral therapy (HAART). Patients with LD phenotype defined by the Multicenter AIDS Cohort Study (MACS) were included. Three different methods were used to define LD severity: both patient and physician evaluation using the HIV Outpatient Study (HOPS) severity scales and the Lipodystrophy Case Definition (LDCD). The HRQOL was evaluated by MOS-HIV Health Survey. Four hundred one patients on HAART for a mean of 108 +/- 52 months were evaluated for LD at the Metabolic Clinic of Modena and Reggio Emilia University were enrolled from January 2003 to July 2006. According to self-perceived or physician-based HOPS, 106 (26.5%) and 122 (30.4%) patients had severe LD. Females had significantly more severe LD. Few HRQOL scores correlated to LD severity using the physician-based score (both HOPSph and LDCD), while all the HRQOL scores correlated with LD severity when a patient-based score was used (HOPSpt). In multiple linear regression analysis, Mental Health HRQOL score, gender, body mass index, age, body image satisfaction were independent predictors of patient-based (HOPSpt) LD, while none of the HRQOL scores, but female gender, age, waist-to-hip ratio, limb fat, and body image satisfaction were correlated with physician-estimated HOPSph LD severity. HRQOL was strongly correlated with LD severity when a patient-based score was used. For an overall assessment of the impact of LD on HIV-infected people, both patient-based and physician-based measures are required.
authors.affiliation: Department of Medicine and Medical Specialties, Infectious Diseases Clinic, University of Modena and Reggio Emilia, Modena, Italy. g.guaraldi@unimo.it
authors.forename: Giovanni
authors.initials: G
authors.lastname: Guaraldi
authors.forename: Rita
authors.initials: R
authors.lastname: Murri
authors.forename: Gabriella
authors.initials: G
authors.lastname: Orlando
authors.forename: Chiara
authors.initials: C
authors.lastname: Giovanardi
authors.forename: Nicola
authors.initials: N
authors.lastname: Squillace
authors.forename: Marcella
authors.initials: M
authors.lastname: Vandelli
authors.forename: Barbara
authors.initials: B
authors.lastname: Beghetto
authors.forename: Giulia
authors.initials: G
authors.lastname: Nardini
authors.forename: Maria
authors.initials: M
authors.lastname: De Paola
authors.forename: Roberto
authors.initials: R
authors.lastname: Esposito
authors.forename: Albert W
authors.initials: AW
authors.lastname: Wu
mesh_terms: D000328:Adult; D023241:Antiretroviral Therapy, Highly Active; D005260:Female; D015658:HIV Infections / Q000150:complications* / Q000188:drug therapy*; D039682:HIV-Associated Lipodystrophy Syndrome / Q000503:physiopathology*; D006306:Health Surveys; D006801:Humans; D016014:Linear Models; D008297:Male; D008875:Middle Aged; D011788:Quality of Life; D012720:Severity of Illness Index; D018434:Sickness Impact Profile